213 related articles for article (PubMed ID: 21866885)
1. Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.
Cami-Kobeci G; Polgar WE; Khroyan TV; Toll L; Husbands SM
J Med Chem; 2011 Oct; 54(19):6531-7. PubMed ID: 21866885
[TBL] [Abstract][Full Text] [Related]
2. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
3. C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.
Cueva JP; Roche C; Ostovar M; Kumar V; Clark MJ; Hillhouse TM; Lewis JW; Traynor JR; Husbands SM
J Med Chem; 2015 May; 58(10):4242-9. PubMed ID: 25898137
[TBL] [Abstract][Full Text] [Related]
4. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
Khroyan TV; Polgar WE; Cami-Kobeci G; Husbands SM; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Mar; 336(3):952-61. PubMed ID: 21177476
[TBL] [Abstract][Full Text] [Related]
5. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
6. Activities of mixed NOP and mu-opioid receptor ligands.
Spagnolo B; Calo G; Polgar WE; Jiang F; Olsen CM; Berzetei-Gurske I; Khroyan TV; Husbands SM; Lewis JW; Toll L; Zaveri NT
Br J Pharmacol; 2008 Feb; 153(3):609-19. PubMed ID: 18059322
[TBL] [Abstract][Full Text] [Related]
7. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
8. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.
Khroyan TV; Wu J; Polgar WE; Cami-Kobeci G; Fotaki N; Husbands SM; Toll L
Br J Pharmacol; 2015 Jan; 172(2):668-80. PubMed ID: 24903063
[TBL] [Abstract][Full Text] [Related]
9. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
Cremeans CM; Gruley E; Kyle DJ; Ko MC
J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.
Brown SM; Holtzman M; Kim T; Kharasch ED
Anesthesiology; 2011 Dec; 115(6):1251-60. PubMed ID: 22037640
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the µ-, δ-, κ-Opioid and Nociceptin Receptors.
Puls K; Schmidhammer H; Wolber G; Spetea M
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164182
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor.
Seki T; Awamura S; Kimura C; Ide S; Sakano K; Minami M; Nagase H; Satoh M
Eur J Pharmacol; 1999 Jul; 376(1-2):159-67. PubMed ID: 10440101
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.
Kallupi M; Shen Q; de Guglielmo G; Yasuda D; Journigan VB; Zaveri NT; Ciccocioppo R
Addict Biol; 2018 Mar; 23(2):585-595. PubMed ID: 28635181
[TBL] [Abstract][Full Text] [Related]
14. Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.
Flynn SM; Epperly PM; Davenport AT; Cami-Kobeci G; Husbands SM; Ko MC; Czoty PW
Neuropsychopharmacology; 2019 Jul; 44(8):1476-1484. PubMed ID: 30970376
[TBL] [Abstract][Full Text] [Related]
15. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
16. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.
Bloms-Funke P; Gillen C; Schuettler AJ; Wnendt S
Peptides; 2000 Jul; 21(7):1141-6. PubMed ID: 10998549
[TBL] [Abstract][Full Text] [Related]
17. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
Zaveri NT; Jiang F; Olsen C; Polgar WE; Toll L
Bioorg Med Chem Lett; 2013 Jun; 23(11):3308-13. PubMed ID: 23623415
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505).
Dietis N; McDonald J; Molinari S; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
Br J Anaesth; 2012 Feb; 108(2):262-70. PubMed ID: 22194444
[TBL] [Abstract][Full Text] [Related]
19. Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity.
Kumar V; Ridzwan IE; Grivas K; Lewis JW; Clark MJ; Meurice C; Jimenez-Gomez C; Pogozheva I; Mosberg H; Traynor JR; Husbands SM
J Med Chem; 2014 May; 57(10):4049-57. PubMed ID: 24761755
[TBL] [Abstract][Full Text] [Related]
20. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group.
Traynor JR; Guo L; Coop A; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
